Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here are three cash-producing companies to avoid and some better opportunities instead.
Health Catalyst (HCAT)
Trailing 12-Month Free Cash Flow Margin: 2.7%
Built on its "Health Catalyst Flywheel" methodology that emphasizes measurable outcomes, Health Catalyst (NASDAQ: HCAT) provides data and analytics technology and services that help healthcare organizations manage their data and drive measurable clinical, financial, and operational improvements.
Why Do We Think HCAT Will Underperform?
- Offerings couldn’t generate interest over the last year as its billings have averaged 14.4% declines
- Gross margin of 51.2% reflects its high servicing costs
- Competitive market means the company must spend more on sales and marketing to stand out even if the return on investment is low
Health Catalyst’s stock price of $1.73 implies a valuation ratio of 0.6x forward price-to-sales. Dive into our free research report to see why there are better opportunities than HCAT.
Monarch (MCRI)
Trailing 12-Month Free Cash Flow Margin: 27.7%
Established in 1993, Monarch (NASDAQ: MCRI) operates luxury casinos and resorts, offering high-end gaming, dining, and hospitality experiences.
Why Is MCRI Risky?
- Sales trends were unexciting over the last five years as its 14.1% annual growth was below the typical consumer discretionary company
- Free cash flow margin is anticipated to expand by 1.5 percentage points over the next year, providing additional flexibility for investments and share buybacks/dividends
- Improving returns on capital suggest management is identifying more profitable investments
At $115.84 per share, Monarch trades at 17.5x forward P/E. Read our free research report to see why you should think twice about including MCRI in your portfolio.
Warby Parker (WRBY)
Trailing 12-Month Free Cash Flow Margin: 2.4%
Founded in 2010, Warby Parker (NYSE: WRBY) designs, manufactures, and sells eyewear, including prescription glasses, sunglasses, and contact lenses, through its e-commerce platform and physical retail locations.
Why Are We Wary of WRBY?
- Revenue base of $911.6 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Subpar operating margin of -1% constrains its ability to invest in process improvements or effectively respond to new competitive threats
- Push for growth has led to negative returns on capital, signaling value destruction
Warby Parker is trading at $26.42 per share, or 53.7x forward P/E. Check out our free in-depth research report to learn more about why WRBY doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
